Roger Perlmutter News
-
Merck & Co., the second-largest U.S. drugmaker, plans to cut jobs at its research laboratories, two months after Roger Perlmutter took helm of the unit.
-
Merck & Co., facing generic competition to what was once its best-selling drug, cut its full-year guidance in anticipation of lower sales and said it would start buying back as much as $15 billion in shares.
-
Merck & Co. hired Roger Perlmutter, Amgen Inc.’s former top scientist, to replace Peter Kim as head of research after several of the drugmaker’s experimental medicines suffered setbacks during testing.
-
Merck & Co. won U.S. marketing approval for Liptruzet, a combination of the company’s Zetia pill and a generic version of Pfizer Inc.’s Lipitor, to lower elevated levels of bad cholesterol.
-
Amgen Inc., the world’s largest biotechnology company, agreed to buy Micromet Inc. in a $1.16 billion deal to gain an experimental leukemia drug.
-
Amgen Inc. ’s osteoporosis drug denosumab was approved by U.S. regulators for reducing fractures in prostate and breast cancer patients, an indication that may boost sales to $2.4 billion in five years.
-
The world’s biggest drugmakers are racing to market the first medicine to tap into a gene mutation that drops heart-attack risk by as much as 88 percent.
-
Amgen Inc.’s bone-strengthening drug denosumab, the focus of the largest development program in the company’s history, was cleared by U.S. regulators for use in postmenopausal women with osteoporosis.
-
Amgen Inc. ’s denosumab delayed the spread of prostate cancer to men’s bones in a study that may help boost sales by $2 billion a year. The company’s shares rose the most since June.
-
Amgen Inc. , the world’s largest biotechnology company, is considering a takeover offer for Actelion Ltd. to gain new medicines for rare diseases, and may approach the Swiss drugmaker as early as this week, said two people with knowledge of the matter.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page